List of Excipients in Branded Drug EQUATE OMEPRAZOLE DELAYED RELEASE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wal-Mart Stores Inc	EQUATE OMEPRAZOLE DELAYED RELEASE	omeprazole	49035-915	CARNAUBA WAX
Wal-Mart Stores Inc	EQUATE OMEPRAZOLE DELAYED RELEASE	omeprazole	49035-915	FERRIC OXIDE RED
Wal-Mart Stores Inc	EQUATE OMEPRAZOLE DELAYED RELEASE	omeprazole	49035-915	FERRIC OXIDE YELLOW

Equate Omeprazole Delayed Release: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 9, 2026

Equate omeprazole delayed release is a private-label OTC proton pump inhibitor, typically sold as a 20 mg delayed-release capsule or tablet. Its commercial position depends on low manufacturing cost, reliable enteric protection, broad retail distribution and consumer familiarity rather than exclusivity from active-ingredient patents. The main strategic opportunity is to improve formulation performance, packaging, tolerability and delivery format while preserving the low-cost OTC price point.

What is Equate Omeprazole Delayed Release?

Equate is Walmart’s private-label consumer health brand. The product is generally supplied by a contract manufacturer under an approved FDA drug application or through an OTC regulatory pathway. The exact manufacturer, dosage form, inactive ingredients and National Drug Code can vary by SKU and supply agreement.

Product characteristic	Commercial profile
Brand	Equate
Active ingredient	Omeprazole, or an approved omeprazole salt such as omeprazole magnesium
Common strength	20 mg
Dosage form	Delayed-release capsule or tablet
Therapeutic class	Proton pump inhibitor
Primary use	Frequent heartburn and acid-related disorders
Regulatory channel	OTC monograph or approved drug application, depending on product configuration
Retail position	Value-priced private label
Primary competitors	Prilosec OTC, Nexium 24HR, generic omeprazole, store-brand lansoprazole and esomeprazole

Omeprazole is acid-labile. The formulation must prevent release in the stomach and deliver the drug to the higher-pH environment of the small intestine. Enteric coating and core protection therefore determine product quality more directly than the active ingredient itself.

What excipients are used in delayed-release omeprazole products?

Public labels for omeprazole delayed-release products commonly identify excipients in five functional groups.

Excipient function	Typical materials	Commercial purpose
Core diluent	Sugar spheres, sucrose, mannitol, lactose or microcrystalline cellulose	Provides processable multiparticulate or tablet cores
Binder and film former	Hypromellose, povidone or hydroxypropyl cellulose	Maintains drug-layer integrity
Alkalizing agent	Sodium hydroxide, disodium phosphate or other alkaline materials	Protects omeprazole from acid-mediated degradation
Enteric polymer	Methacrylic acid copolymers, cellulose acetate phthalate or hypromellose phthalate	Prevents gastric release
Coating aids	Polyethylene glycol, talc, titanium dioxide, polysorbate or mineral excipients	Controls flexibility, adhesion, opacity and processing

The exact inactive-ingredient profile is product-specific. DailyMed labels for omeprazole delayed-release capsules show the use of coated pellets, hypromellose-based layers, alkaline stabilizers and methacrylic acid copolymers.[1] FDA guidance recognizes enteric protection, dissolution performance and stability as central quality attributes for delayed-release products.[2]

Core and alkaline protection

Omeprazole degrades rapidly under acidic conditions. A commercial formulation usually uses an alkaline microenvironment around the drug before applying the enteric layer. The excipient strategy must balance:

• Sufficient alkalinity to limit degradation.
• Low water activity during manufacture and storage.
• Compatibility with capsule shells or tablet compression.
• Uniform drug loading across pellets or granules.
• Acceptable dissolution after gastric transit.

Excess alkalinity can create processing problems, alter coating behavior or affect dissolution. Insufficient alkalinity can produce assay loss, related substances and inconsistent shelf life.

Enteric polymer selection

Methacrylic acid copolymers are common because their dissolution threshold can be selected by polymer grade and formulation design. A lower-pH polymer can support earlier intestinal release, while a higher-pH polymer can improve gastric resistance.

The commercial trade-off is straightforward:

Design choice	Advantage	Risk
Thicker enteric coating	Stronger acid resistance	Higher cost and slower release
Lower-threshold polymer	Earlier intestinal release	Greater risk of premature gastric release
Higher-threshold polymer	Strong gastric protection	Delayed release or incomplete dissolution
More talc	Better anti-tack performance	Potential coating defects or dissolution impact
More plasticizer	Flexible coating	Increased moisture sensitivity or migration

How strong is the patent estate for Equate omeprazole delayed release?

The active-ingredient patent estate is weak from a market-entry perspective because omeprazole has been generic for many years. The relevant commercial protection is more likely to involve formulation know-how, regulatory exclusivity, trademarks, manufacturing controls and private-label supply arrangements.

The original prescription product, Prilosec, was developed by AstraZeneca and approved by FDA in 1989. Omeprazole delayed-release products have since entered the generic and OTC markets through multiple manufacturers.[3]

IP category	Current commercial relevance
Omeprazole compound patents	Generally expired
Basic delayed-release formulation patents	Generally expired or difficult to enforce broadly
Product-specific formulation patents	Possible, but scope depends on the manufacturer and formulation
Method-of-use patents	Limited value for routine OTC heartburn claims
Manufacturing know-how	Potentially important
Coating process and pellet architecture	Potentially protectable if technically differentiated
Brand and private-label rights	Commercially important for Equate
Packaging and dosing presentation	Possible design and trade-dress protection

A new patent position would require more than substituting one conventional enteric polymer for another. A stronger formulation strategy would target a measurable technical result, such as lower impurity formation, improved moisture stability, reduced coating weight, faster post-gastric release or a novel multiparticulate architecture.

What FDA regulatory status applies to Equate omeprazole?

OTC omeprazole products are regulated under the FDA framework for proton pump inhibitor products and associated labeling requirements. FDA’s OTC monograph system changed substantially under the CARES Act, with final monograph orders replacing the prior monograph rulemaking model.[4]

A product marketed under the OTC pathway must meet applicable conditions relating to:

• Active ingredient and dosage.
• Indication and consumer labeling.
• Directions for use.
• Warnings and duration limits.
• Dosage form and quality specifications.
• Manufacturing under current good manufacturing practice requirements.

Products outside the applicable monograph conditions may require an approved new drug application. Generic prescription products generally rely on abbreviated new drug applications and must demonstrate pharmaceutical equivalence and bioequivalence to the reference product.

What is the Orange Book status of Equate omeprazole?

The Orange Book primarily tracks approved prescription drug applications and listed patents. A store-brand OTC product may not appear as a separately branded Orange Book product in the same way as a prescription generic. The applicable regulatory status depends on whether the product is marketed under an NDA, ANDA or OTC monograph pathway.

For a specific Equate SKU, the most reliable identification route is the package NDC, manufacturer or distributor name and dosage form. The patent analysis changes materially between an OTC monograph product and an ANDA-listed product.

When does omeprazole lose exclusivity?

Omeprazole compound exclusivity has already expired. The market has long supported generic prescription omeprazole and multiple OTC competitors. The remaining barriers are operational rather than molecule-based.

Exclusivity or barrier	Status
Active ingredient exclusivity	Expired
Original prescription brand exclusivity	Expired
Generic entry	Established
OTC competitive entry	Established
Formulation-specific protection	Product-dependent
Private-label retail access	Controlled by retailer and supplier agreements
Manufacturing qualification	Material practical barrier
Consumer brand loyalty	Moderate, but price-sensitive

What formulation patents could protect an improved Equate product?

A future formulation patent could focus on one or more of the following technical features:

1. A low-moisture omeprazole pellet with improved long-term impurity control.
2. A multilayer pellet with a defined alkaline subcoat and enteric polymer sequence.
3. A tablet containing compressed enteric-coated pellets that survives compression without rupturing.
4. A sprinkle formulation that preserves acid resistance after opening.
5. A reduced-coating-weight system with equivalent gastric protection.
6. A formulation that releases omeprazole within a narrower intestinal pH window.
7. A preservative-free liquid or reconstitutable product with controlled degradation.
8. A capsule shell or blister system that reduces humidity exposure.

Patent value would depend on claim breadth, reproducibility, comparative data and the ability to detect infringement. A patent limited to a conventional excipient substitution would likely have weaker defensive value than a claim covering a defined structure-function relationship supported by dissolution and stability data.

What commercial opportunities exist in excipient optimization?

Lower-cost enteric coating

The largest immediate opportunity is cost reduction without sacrificing dissolution. Coating solids, process time, drying energy, yield loss and solvent or aqueous-processing requirements can materially affect unit economics.

A private-label manufacturer could evaluate:

• Lower coating weight.
• Higher-solids aqueous dispersions.
• Reduced coating time.
• Alternative plasticizer systems.
• Improved anti-tacking agents.
• Continuous coating or high-throughput fluid-bed processing.

The product must still meet acid-resistance and intestinal-release specifications.

Moisture and heat stability

Omeprazole products are sensitive to moisture, heat and formulation microenvironment. Excipient and packaging changes can reduce product loss during distribution through hot and humid markets.

Commercial options include:

• Desiccant-equipped bottles.
• High-barrier foil blisters.
• Lower-permeability bottle systems.
• Moisture-scavenging closures.
• More robust alkaline subcoats.
• Low-water-activity excipient systems.

Packaging can create a larger practical benefit than a marginal change in the active formulation, especially for low-margin OTC products distributed through mass retail.

New delivery formats

Equate could extend the product line through differentiated formats:

Format	Target consumer	Opportunity
Delayed-release capsule	Existing adult users	Lowest-risk line extension
Delayed-release tablet	Consumers preferring tablets	Potentially simpler logistics
Sprinkle capsule	Patients with swallowing difficulty	Higher-value niche
Mini-tablet sachet	Pediatric or geriatric use	Regulatory and dosing complexity
Chewable acid-control combination	Convenience users	More complex stability profile
14-day calendar pack	Self-treatment users	Compliance and retail merchandising
Unit-dose blister	Travel and adherence	Higher packaging cost, better portability

A chewable or liquid product creates substantial technical risk because omeprazole must remain protected from acidic conditions until intestinal release. Simple taste masking is not sufficient.

Which companies challenge Equate in the OTC market?

The main competitive set includes:

• Procter & Gamble’s Prilosec OTC.
• Haleon’s Nexium 24HR.
• Perrigo private-label products.
• Dr. Reddy’s Laboratories and other generic manufacturers.
• Retailer brands sold by CVS, Walgreens, Amazon and supermarket chains.
• Lansoprazole and famotidine products competing for the same heartburn consumer.

Omeprazole competes on price and established consumer recognition. Esomeprazole competes on perceived potency and brand positioning. Famotidine competes on faster perceived onset and intermittent-use positioning, even though it is pharmacologically distinct.

What generic launch risks exist for an improved product?

A conventional Equate omeprazole product faces limited molecule-level launch risk because generic suppliers are already established. The principal risks are:

• Supplier failure or manufacturing interruption.
• Out-of-specification dissolution.
• Rising enteric-polymer or capsule costs.
• Private-label contract loss.
• Retail price compression.
• Packaging-related stability failures.
• FDA inspection findings.
• Product recalls caused by impurities or dissolution variability.
• Consumer switching to esomeprazole or famotidine.

A differentiated formulation could improve margins, but the product must preserve the price advantage expected from a Walmart private-label medicine. Premium excipients are justified only when they reduce manufacturing loss, extend shelf life or support a defensible dosage form.

How does Equate omeprazole compare with Prilosec OTC and Nexium 24HR?

Factor	Equate omeprazole	Prilosec OTC	Nexium 24HR
Active ingredient	Omeprazole or approved salt	Omeprazole	Esomeprazole
Positioning	Value private label	Established branded OTC	Branded premium OTC
Primary advantage	Price and retail access	Brand recognition	Potency and brand perception
Patent dependence	Low	Historical brand/formulation rights	More relevant historical formulation and brand rights
Excipient opportunity	Cost, stability and format	Brand-supported premium features	Premium packaging and positioning
Main risk	Margin compression	Brand substitution	Higher price sensitivity

What licensing deals and manufacturing barriers matter?

The most relevant commercial agreements are generally private-label supply, contract manufacturing, technology-transfer and packaging arrangements rather than drug-discovery licenses. A supplier may control:

• Pelletization technology.
• Enteric-coating process parameters.
• Stability data.
• Approved manufacturing sites.
• Drug-master-file information.
• Scale-up knowledge.
• Specialized capsule or blister equipment.

A retailer switching suppliers must manage regulatory filings, process validation, analytical method transfer, stability studies and inventory continuity. These execution barriers can preserve a supplier relationship even when no blocking patent remains.

Key Takeaways

• Equate omeprazole delayed release is primarily a value-priced OTC private-label product.
• Omeprazole compound exclusivity has expired, and generic competition is established.
• Excipient strategy centers on alkaline protection, enteric coating, moisture control and dissolution consistency.
• The strongest commercial opportunities are low-cost coating processes, improved stability packaging and differentiated delivery formats.
• Formulation patents may be available for technically demonstrated pellet architecture, coating systems or stability improvements.
• The exact FDA and Orange Book status depends on the product’s NDC, dosage form and regulatory application.
• Manufacturing know-how, supply agreements and retail access are more important barriers than active-ingredient patents.
• A successful line extension must improve performance without eliminating the product’s low-cost private-label economics.

FAQs About Equate Omeprazole Delayed Release

Is Equate omeprazole the same as Prilosec OTC?

Both products generally use omeprazole as the active ingredient at the common 20 mg OTC strength, but inactive ingredients, manufacturer, dosage form, packaging and regulatory application may differ.

Can excipients change the effectiveness of omeprazole delayed release?

Yes. Alkaline stabilizers, enteric polymers, coating thickness, moisture exposure and pellet structure can affect stability, gastric resistance and intestinal dissolution.

Does omeprazole have biosimilar risk?

No. Omeprazole is a small-molecule drug, not a biologic. The relevant competitive pathway is generic or OTC product entry, not biosimilar approval.

Can a private-label omeprazole formulation receive new patent protection?

Yes, if the formulation contains a novel and nonobvious technical feature supported by reproducible performance data. Conventional excipient substitution alone may provide limited patent strength.

What is the most valuable commercial improvement for Equate omeprazole?

A formulation and packaging system that reduces moisture-driven degradation while lowering coating and manufacturing costs is likely to offer the clearest commercial value.

References

1. National Library of Medicine. (n.d.). DailyMed: Omeprazole delayed-release capsule labeling. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2018). Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. FDA.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. FDA.